<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03051945</url>
  </required_header>
  <id_info>
    <org_study_id>00087544</org_study_id>
    <nct_id>NCT03051945</nct_id>
  </id_info>
  <brief_title>Endogenous Opioid Modulation by Ketamine</brief_title>
  <official_title>Endogenous Opioid Modulation by Ketamine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Demonstrate the acute effects of ketamine on endogenous µ-opioid neurotransmission in humans.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will test the hypothesis that the rapidly-acting antidepressant ketamine improves
      core depressive symptoms by acutely activating the brain's endogenous µ-opioid system.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Unable to perform brain imaging
  </why_stopped>
  <start_date type="Anticipated">August 2019</start_date>
  <completion_date type="Actual">August 1, 2019</completion_date>
  <primary_completion_date type="Actual">August 1, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hamilton Depression Rating Scale at 24 hours, change from baseline</measure>
    <time_frame>24 hr</time_frame>
    <description>total score on the 17-item Hamilton Depression Rating Scale</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Ketamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ketamine will be infused via intravenous catheter over 40 minutes (0.75 mg/kg/hr over 40 minutes, 0.5 mg/kg total).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline will be infused via intravenous catheter over 40 minutes (0.75 mg/kg/hr over 40 minutes, 0.5 mg/kg total).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine Hydrochloride</intervention_name>
    <description>Study drug will be infused while the participant sits or lies in a comfortable position. The dose of ketamine used does not cause unconsciousness but may cause perceptual disturbances.</description>
    <arm_group_label>Ketamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-65

          -  DSM-5 major depressive disorder

          -  Current moderate-to-severe, treatment-resistant, depressive episode

          -  Patient Health Questionnaire (PHQ-9) total score ≥ 10

          -  PHQ-9 item score ≥ 2 on &quot;Little interest or pleasure&quot; item

          -  PHQ-9 item score ≥ 2 on &quot;Feeling down, depressed, or hopeless&quot; item

          -  Medical documentation of depression for at least 2 months

          -  Inadequate response to at least one adequate antidepressant medication trial in the
             current episode

        Exclusion Criteria:

          -  Current episode duration &gt;5 years

          -  Moderate-to-severe DSM-5 substance use disorder (past year)

          -  Cognitive disorder (past year)

          -  Post-traumatic stress disorder (past year)

          -  Obsessive compulsive disorder (past year)

          -  Personality disorder (past year)

          -  Positive urine drug screen

          -  Psychotic symptoms

          -  Mania

          -  Significant neurologic disorder or injury

          -  Breastfeeding or pregnancy

          -  Imminent suicide risk

          -  Current use of CYP3A4 inhibitors (e.g., ketoconazole or erythromycin)

          -  Other unstable psychiatric or medical condition requiring a higher level of care

          -  Contraindication to ketamine, MRI, or PET
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>February 7, 2017</study_first_submitted>
  <study_first_submitted_qc>February 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 14, 2017</study_first_posted>
  <last_update_submitted>January 24, 2020</last_update_submitted>
  <last_update_submitted_qc>January 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Utah</investigator_affiliation>
    <investigator_full_name>Brian Mickey</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

